Resumo

ARIAS-HERNANDEZ, Andersson  e  RINCON-CASTILLO, Diego. Metformin and glyburide in the treatment of gestational diabetes. Medicas UIS [online]. 2015, vol.28, n.3, pp.337-343. ISSN 0121-0319.  https://doi.org/10.18273/revmed.v28n3-2015008.

Introduction: Gestational diabetes is an impaired glucose tolerance of variable severity first recognized in the current pregnancy. Insulin has been the standard drug treatment for gestational diabetes, however metformin and glyburide are therapeutic alternatives to control glycemia. Objective: Determine the advantages of metformin and glyburide over insulin in the treatment of gestational diabetes. Materials and methods: A systematic research was performed in the databases Medline (PubMed) and Scielo. The DeCS terms used were: "Diabetes Gestacional", "Gliburida", and "Metformina" in different combinations; MeSH counterparts were: "Diabetes, Gestational", "Glyburide" and "Metformin". The search obtained covered 130 articles, of which 53 were selected. Results: Glyburide is a category C drug in pregnancy. Their concentrations in umbilical cord are insignificant and is considered safe. Its success rate to achieve glycemic control ranges from 79% to 86%. Metformin is a category B drug in pregnancy. It has shown no teratogenic effects in the first trimester of pregnancy. It achieves glycemic control in 24 hours. Conclusions: Metformin and glyburide achieved glycemic control values in gestational diabetes similar to insulin. They do not increase the teratogenesis in the first trimester of pregnancy. Perinatal complications from its use should be more studied. MÉD UIS. 2015;28(3):337-43.

Palavras-chave : Diabetes Gestational; Metformin; Glyburide.

        · resumo em Espanhol     · texto em Espanhol     · Espanhol ( pdf )